Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: CROSSJECT

Market Cap 105M 122M 96.93M 90.73M 170M 11.58B 173M 1.14B 446M 5.63B 457M 447M 19.51B P/E Ratio 2026 *
4.71x
P/E Ratio 2027 * 3.72x
Enterprise Value 87.29M 101M 80.43M 75.29M 141M 9.61B 143M 950M 370M 4.68B 379M 371M 16.19B EV / Sales 2026 *
1.44x
EV / Sales 2027 * 1.38x
Free-Float
89.86%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 63 08/08/2001
Director of Finance/CFO - 25/03/2026
Corporate Officer/Principal - 20/08/2024
Director TitleAgeSince
Chairman 67 26/06/2009
Director/Board Member 67 -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-3.77%-4.20%-17.43%-71.69% 91.64M
+0.11%+4.08%+92.46%+27.57% 87.79M
Average -1.83%-0.06%+37.51%-22.06% 89.72M
Weighted average by Cap. -1.87%-0.15%+36.34%-23.12%

Financials

2026 *2027 *
Net sales 60.8M 70.39M 56.03M 52.44M 98.28M 6.69B 99.81M 662M 258M 3.26B 264M 259M 11.28B 42.3M 48.98M 38.98M 36.49M 68.38M 4.66B 69.44M 460M 179M 2.27B 184M 180M 7.85B
Net income 28.3M 32.77M 26.08M 24.41M 45.75M 3.11B 46.46M 308M 120M 1.52B 123M 120M 5.25B 7.75M 8.97M 7.14M 6.68M 12.53M 853M 12.72M 84.33M 32.88M 415M 33.68M 32.96M 1.44B
Net Debt -17.9M -20.72M -16.49M -15.44M -28.94M -1.97B -29.38M -195M -75.94M -959M -77.78M -76.12M -3.32B -47M -54.42M -43.31M -40.54M -75.98M -5.17B -77.15M -511M -199M -2.52B -204M -200M -8.72B
Logo CROSSJECT
Crossject specializes in manufacturing and marketing needleless drug self-injection. The group provides Zeneo, a prefilled and single-use device that can be used for intradermal, subcutaneous and intramuscular injections.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!